Isocitrate Dehydrogenase (IDH) Inhibitors Global Market Report 2025

The isocitrate dehydrogenase (IDH) inhibitors market size has grown exponentially in recent years. It will grow from $1.94 billion in 2024 to $2.46 billion in 2025 at a compound annual growth rate (CAGR) of 27%. The growth during the historic period can be credited to the rising occurrence of hematologic cancers, advancements in genetic profiling within oncology, successful clinical outcomes of targeted therapies, the implementation of precision medicine initiatives, and increased healthcare expenditures in oncology.

The isocitrate dehydrogenase (IDH) inhibitors market size is expected to see exponential growth in the next few years. It will grow to $6.34 billion in 2029 at a compound annual growth rate (CAGR) of 26.7%. The projected growth can be attributed to favorable reimbursement policies, an increasing prevalence of blood cancers, heightened awareness among oncologists, greater adoption of precision medicine, and the expansion of healthcare infrastructure and oncology centers. Key trends anticipated during the forecast period include progress in genomic and molecular diagnostics, strategic collaborations and licensing agreements, innovations in drug delivery systems, enhancements in diagnostic technologies, and the development of combination therapies.

The rising incidence of acute myeloid leukemia (AML) is expected to drive the growth of the isocitrate dehydrogenase (IDH) inhibitors market in the coming years. AML is a rapidly progressing cancer of the blood and bone marrow marked by the abnormal proliferation of white blood cells, which disrupts normal blood cell production. This increase in AML cases is largely attributed to the aging population, as older individuals are more susceptible to developing this aggressive cancer due to age-related changes in bone marrow function and immune response. IDH inhibitors play a crucial role in treating AML by targeting and blocking mutated IDH enzymes, thereby restoring normal blood cell development and slowing the progression of leukemia. For example, according to a February 2023 report by the Leukaemia Foundation, an Australia-based non-profit organization, between 2022 and 2035, over 7,000 children, 6,000 young adults, and 108,000 adults aged 25-65 are expected to be diagnosed with blood cancers, predominantly acute lymphoblastic leukemia (ALL), AML, and non-Hodgkin lymphoma (NHL). As a result, the growing frequency of AML is anticipated to significantly boost the IDH inhibitors market.

Major companies in the isocitrate dehydrogenase (IDH) inhibitors market are prioritizing regulatory approvals to expand clinical indications, accelerate time-to-market, and strengthen their competitive positioning in the treatment of IDH-mutant cancers. Regulatory approvals, granted by health authorities, confirm a drug’s safety and efficacy and are essential for commercial launch. For example, in August 2024, Servier Laboratoires, a France-based pharmaceutical company, received FDA approval for VORANIGO (vorasidenib) tablets - the first targeted therapy approved for patients with Grade 2 IDH-mutant glioma, including astrocytoma and oligodendroglioma with IDH1 or IDH2 mutations. In the Phase 3 INDIGO trial, VORANIGO demonstrated a median progression-free survival of 27.7 months compared to 11.1 months with placebo. The oral formulation offers a well-tolerated and convenient treatment option, representing a significant advancement for patients with limited existing therapies.

In October 2022, Novo Nordisk A/S, a Denmark-based pharmaceutical company, acquired Forma Therapeutics for $1.1 billion. The acquisition aims to strengthen Novo Nordisk’s scientific capabilities and pipeline in hemoglobinopathies by expanding its portfolio to include treatments for sickle cell disease and other rare blood disorders. Forma Therapeutics, a US-based biopharmaceutical company, is known for developing innovative therapies for various cancers, including those targeting mutated isocitrate dehydrogenase (IDH).

Major players in the isocitrate dehydrogenase (idh) inhibitors market are Roche Holding AG, Merck & Co., Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Daiichi Sankyo Company Limited, Les Laboratoires Servier, Evotec SE, HUTCHMED (China) Limited, Rigel Pharmaceuticals Inc., CStone Pharmaceuticals, Forma Therapeutics Holdings Inc., Philogen S.p.A., Kura Oncology, Inc., Philogen S.p.A., Agios Pharmaceuticals Inc., Adooq Bioscience LLC, Taiho Pharmaceutical Co. Ltd., Celgene Corporation, Focus Biomolecules LLC, InvivoChem LLC.

North America was the largest region in the isocitrate dehydrogenase (IDH) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in isocitrate dehydrogenase (IDH) inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the isocitrate dehydrogenase (IDH) inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Isocitrate dehydrogenase (IDH) Inhibitors are a category of targeted cancer treatments aimed at inhibiting the activity of mutated IDH1 and IDH2 enzymes. These enzymes play a role in cellular metabolism, and mutations in their genes can result in abnormal cell proliferation and cancer progression.

The primary types of isocitrate dehydrogenase (IDH) inhibitors include IDH1 mutant medullary malignant tumors, IDH2 mutant medullary malignant tumors, and others. An IDH1 mutant medullary malignant tumor is a cancer that begins in the central (medullary) part of a tissue or organ and involves a mutation in the IDH1 gene. These therapies encompass various molecular forms, such as monoclonal antibodies, peptides, small molecules, and others, and can be administered via oral, parenteral, subcutaneous, and topical routes. Applications include FLT3 inhibitors, DH inhibitors, hedgehog pathway inhibitors, and more.

The isocitrate dehydrogenase (IDH) inhibitors market research report is one of a series of new reports that provides isocitrate dehydrogenase (IDH) inhibitors market statistics, including isocitrate dehydrogenase (IDH) inhibitors industry global market size, regional shares, competitors with an isocitrate dehydrogenase (IDH) inhibitors market share, detailed isocitrate dehydrogenase (IDH) inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the isocitrate dehydrogenase (IDH) inhibitors industry. This isocitrate dehydrogenase (IDH) inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The isocitrate dehydrogenase (IDH) inhibitors market consists of sales of selective IDH1 inhibitors, selective IDH2 inhibitors, dual IDH1/IDH2 inhibitors, combination therapies, and delivery forms. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods, such as formulation development, packaging, and regulatory support.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.